Profile data is unavailable for this security.
About the company
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
- Revenue in INR (TTM)7.57bn
- Net income in INR879.46m
- Incorporated1984
- Employees763.00
- LocationBliss GVS Pharma Ltd102Hyde Park,Sakivihar Road, Andheri-EastMUMBAI 400072IndiaIND
- Phone+91 2 242160000
- Fax+91 2 228563930
- Websitehttps://www.blissgvs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bajaj Healthcare Ltd | 4.98bn | 212.66m | 8.89bn | 1.06k | 41.77 | -- | 18.14 | 1.78 | 7.71 | -18.22 | 180.50 | -- | -- | -- | -- | 4,684,510.00 | -- | 9.86 | -- | 17.42 | 42.26 | 26.47 | 4.27 | 8.57 | -- | 1.66 | -- | -- | -0.9704 | 15.53 | -39.73 | 23.16 | 60.82 | 31.95 |
Jagsonpal Pharmaceuticals Ltd | 2.21bn | 245.16m | 9.44bn | 940.00 | 38.41 | -- | 35.95 | 4.28 | 9.30 | 9.30 | 83.51 | -- | -- | -- | -- | 2,347,522.00 | -- | 10.02 | -- | 12.51 | 54.09 | 58.47 | 11.11 | 8.03 | -- | 30.39 | -- | 36.24 | 8.79 | 13.33 | 41.72 | -- | -39.20 | 118.67 |
Windlas Biotech Ltd | 6.00bn | 526.38m | 11.43bn | 1.05k | 21.82 | -- | 17.28 | 1.90 | 25.18 | 25.18 | 286.98 | -- | -- | -- | -- | 5,723,394.00 | -- | -- | -- | -- | 37.06 | -- | 8.77 | -- | -- | 59.55 | -- | -- | 10.12 | -- | 11.91 | -- | -- | -- |
Vimta Labs Ltd | 3.20bn | 413.41m | 11.60bn | 1.37k | 28.47 | -- | 15.36 | 3.62 | 18.37 | 18.37 | 142.48 | -- | -- | -- | -- | 2,342,054.00 | -- | 10.50 | -- | 12.94 | 75.80 | 72.82 | 12.90 | 11.92 | -- | 28.50 | -- | 12.37 | 14.34 | 11.64 | 16.55 | 24.00 | 15.39 | 0.00 |
Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 11.80bn | 38.00 | 125.35 | 45.43 | 131.43 | 26.21 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
Lincoln Pharmaceuticals Ltd | 5.51bn | 872.70m | 11.97bn | 1.70k | 13.72 | -- | 12.27 | 2.18 | 43.57 | 43.57 | 274.88 | -- | -- | -- | -- | 3,238,331.00 | -- | 13.75 | -- | 16.82 | 54.00 | 50.74 | 15.85 | 14.11 | -- | 41.54 | -- | 3.94 | 8.09 | 7.13 | 5.11 | 16.06 | 7.60 | 0.00 |
Kopran Ltd | 5.79bn | 403.74m | 12.04bn | 394.00 | 30.03 | -- | 22.76 | 2.08 | 8.32 | 8.32 | 119.70 | -- | -- | -- | -- | 14,693,070.00 | -- | 8.64 | -- | 12.88 | 35.60 | 34.36 | 6.97 | 8.71 | -- | 36.80 | -- | -- | 15.38 | 11.85 | -55.38 | 5.86 | 39.08 | -- |
Bliss GVS Pharma Ltd | 7.57bn | 879.46m | 12.46bn | 763.00 | 14.38 | -- | 10.90 | 1.65 | 8.28 | 8.28 | 71.43 | -- | -- | -- | -- | 9,919,995.00 | -- | 7.72 | -- | 10.13 | 47.73 | 38.59 | 11.88 | 10.80 | -- | 10.26 | -- | 8.26 | 0.553 | 15.07 | 371.13 | 107.42 | 27.16 | -12.94 |
Beta Drugs Ltd | 2.56bn | 347.57m | 12.95bn | 315.00 | 37.27 | 9.12 | 28.30 | 5.06 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
Zota Health Care Ltd | 1.68bn | -100.65m | 12.96bn | 338.00 | -- | -- | 182.54 | 7.73 | -3.95 | -3.95 | 65.73 | -- | -- | -- | -- | 4,961,589.00 | -- | 2.13 | -- | 2.78 | 43.59 | 32.39 | -6.00 | 2.01 | -- | -1.81 | -- | 115.52 | 6.68 | 12.45 | -164.81 | -- | 56.84 | -14.14 |
Syncom Formulations (India) Ltd | 2.50bn | 263.83m | 13.11bn | 799.00 | 41.03 | -- | 42.33 | 5.25 | 0.34 | 0.34 | 3.26 | -- | -- | -- | -- | 3,126,329.00 | -- | 7.69 | -- | 10.30 | 39.33 | 31.92 | 10.56 | 8.73 | -- | 4.72 | -- | -- | 2.09 | 7.17 | 1.42 | 18.34 | 25.48 | -- |
Hester Biosciences Ltd | 2.93bn | 184.70m | 14.39bn | 693.00 | 75.07 | -- | 36.64 | 4.92 | 22.54 | 22.54 | 352.21 | -- | -- | -- | -- | 4,222,078.00 | -- | 8.22 | -- | 10.27 | 67.10 | 69.31 | 7.00 | 16.15 | -- | 2.15 | -- | 22.67 | 13.23 | 14.30 | -32.28 | 0.7733 | 27.62 | -4.36 |
Ngl Fine Chem Ltd | 3.17bn | 380.04m | 15.54bn | 343.00 | 40.89 | -- | 31.25 | 4.90 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
Holder | Shares | % Held |
---|---|---|
Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 6.90m | 6.59% |
Dimensional Fund Advisors LPas of 04 Apr 2024 | 353.83k | 0.34% |
American Century Investment Management, Inc.as of 04 Apr 2024 | 31.82k | 0.03% |
Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 23.89k | 0.02% |
DFA Australia Ltd.as of 31 Dec 2023 | 2.57k | 0.00% |
Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 734.00 | 0.00% |